Vesicular neurotransmitter transporters in huntington's disease: Initial observations and comparison with traditional synaptic markers

Synapse

Volumn 41, Issue 4, 2001, Pages 329-336

  Suzuki, Masahiko ^a   Desmond, Timothy J ^b   Albin, Roger L ^c,d,e   Frey, Kirk A ^a,f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Choline acetyltransferase; VAChT; VMAT2

Indexed keywords

ACETYLCHOLINE; DOPAMINE; DOPAMINE PLASMALEMMAL TRANSPORTER; MEMBRANE RECEPTOR; MONOAMINE; NEUROTRANSMITTER; UNCLASSIFIED DRUG; VESICULAR ACETYCHOLINE TRANSPORTER TYPE 2; VESICULAR MONOAMINE TRANSPORTER TYPE 2;

ADULT; AGED; ARTICLE; ATROPHY; AUTORADIOGRAPHY; BINDING SITE; CASE REPORT; CELL MEMBRANE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; CORPUS STRIATUM; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; LIGAND BINDING; NERVE CELL; NERVE CELL DEGENERATION; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; SYNAPSE; SYNAPTIC TRANSMISSION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; AUTORADIOGRAPHY; CARRIER PROTEINS; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC FIBERS; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FLUMAZENIL; GABA MODULATORS; HUMANS; HUNTINGTON DISEASE; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROPEPTIDES; POSTMORTEM CHANGES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA-A; SUBSTANTIA NIGRA; SYNAPSES; TETRABENAZINE; TRITIUM; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS; VESICULAR TRANSPORT PROTEINS;

EID: 0035885487     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.1089     Document Type: Article

References (52)

1. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia
2. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations
3. Expression of the vesicular acetylcholine transporter is unaltered by pharmacological interventions in cholinergic transmission
4. Chemical pathology of Huntington's disease
5. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia
6. Decreased striatal monoaminergic terminals in Huntington disease
7. D2 receptors in Huntington's disease: Positron emission tomography findings and clinical correlates
8. Temporal lobe central benzodiazepine binding in unilateral mesial temporal lobe epilepsy
9. Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35,428) in the monkey brain
10. Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease
11. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum
12. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease
13. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease
14. A rapid radiochemical method for the determination of choline acetyltransferase
15. Striatal quinolinic acid lesions increase [3H]WIN 35,428 binding to the dopamine transporter
16. Neuropathology of the substantia nigra
17. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease
18. Striosomes and extrastriosomal matrix contain different amounts of immunoreactive choline acetyltransferase in the human striatum
19. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease
20. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
21. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HM-PAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease
22. Studies on neurotransmitter markers and striatal neuronal cell density in Huntington's disease and dentatorubropallidoluysian atrophy
23. Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum
24. [3H]Vesamicol binding in human brain cholinergic deficiency disorders
25. Evaluation of specific binding of [11C]dihydrotetrabenazine using active (+) and inactive (-) enantiomers
26. Autoradiographic visualization of dopamine D-2 receptors in the monkey brain using the selective benzamide drug [3H]raclopride
27. Morphometric studies of the neuropathological changes in choreatic diseases
28. Huntington's disease gene (IT15) is widely expressed in human and rat tissues
29. Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea
30. Choline acetylase and glutamic acid decarboxylase in Huntington's chorea. A preliminary study
31. Autoradiographic quantification of the vesamicol receptor in Alzheimer's disease
32. Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex
33. A quantitative investigation of the substantia nigra in Huntington's disease
34. Changes in [3H]muscimol binding in substantia nigra, entopeduncular nucleus, globus pallidus, and thalamus after striatal lesions as demonstrated by quantitative receptor autoradiography
35. The occurrence of large acetylcholinesterase-containing neurons in human neostriatum as disclosed in normal and Alzheimer-diseased brains
36. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain
37. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models
38. Dementia in Huntington's disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex
39. Heterogeneous dopamine receptor changes in early and late Huntington's disease
40. Choline acetyltransferase activity and [3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease. Parkinson's disease, and rats with basal forebrain lesions
41. Measurement of protein using bicinchoninic acid
42. Neurochemical alterations in Huntington's chorea: A study of post-mortem brain tissue
43. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study
44. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments
45. [3H]Methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity
46. Neuropathological classification of Huntington's disease
47. Benzodiazepine and GABA receptors in early Huntington's disease
48. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease
49. Effects of postmortem delay and temperature on neurotransmitter receptor binding in a rat model of the human autopsy process
50. Neurotransmitter receptor alterations in Huntington's disease: Autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes
51. Ornithine aminotransferase in Huntington's disease